New drug offers hope for patients who Can't tolerate sunlight

NCT ID NCT05308472

First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 22 times

Summary

This study tested an experimental drug called bitopertin in 75 adults with erythropoietic protoporphyria (EPP), a rare condition that causes severe pain from sunlight exposure. The goal was to see if the drug safely lowers harmful substances in the blood and allows more time in the sun without pain. Results are available from this completed Phase 2 trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ERYTHROPOIETIC PROTOPORPHYRIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina, 27157, United States

  • Einstein Medical Center

    Philadelphia, Pennsylvania, 19141, United States

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mount Sinai Hospital

    New York, New York, 10029, United States

  • University of Alabama Hospital

    Birmingham, Alabama, 35233, United States

  • University of California San Francisco

    San Francisco, California, 94117, United States

  • University of Miami Miller School of Medicine

    Miami, Florida, 33136, United States

  • University of Texas

    Galveston, Texas, 77550, United States

Conditions

Explore the condition pages connected to this study.